openPR Logo
Press release

Corneal Ulcer Pipeline Insight 2025: 15+ Emerging Anti-Infective and Regenerative Therapies Targeting Sight-Threatening Infections | DelveInsight

07-21-2025 04:13 PM CET | Health & Medicine

Press release from: DelveInsight

Corneal Ulcer Pipeline

Corneal Ulcer Pipeline

DelveInsight's "Corneal Ulcer - Pipeline Insight, 2025" report offers a detailed overview of the therapeutic advancements underway for corneal ulcers, a serious ocular condition often caused by bacterial, viral, fungal, or parasitic infections. Left untreated, corneal ulcers can lead to scarring, vision impairment, or even blindness, making timely intervention and effective therapy critical.

The current pipeline features a growing number of targeted anti-infectives, corticosteroid formulations, and regenerative approaches aimed at addressing the underlying infection while promoting epithelial repair. With increasing cases of antimicrobial resistance and complications from delayed diagnosis, there is a pressing need for more effective, fast-acting treatments that go beyond conventional antibiotic or antifungal eye drops.

Key therapies in development include APP13007 by Formosa Pharmaceuticals, a Phase III corticosteroid nanoparticle formulation, and RGN-259 by RegeneRx, a thymosin beta-4-based eye drop being studied for both infectious keratitis and epithelial healing. Several other candidates, including bioactive peptides and stem cell-based therapies, are in early clinical stages, reflecting a shift toward multi-modal, tissue-protective strategies.

Biopharma companies such as Formosa, RegeneRx, Dompé, and FiteBac are actively shaping the space, leveraging orphan drug designations and novel delivery technologies to accelerate development. As innovation intensifies, the corneal ulcer pipeline shows strong potential to deliver next-generation solutions for this vision-threatening condition.

Interested in learning more about the current treatment landscape and the key drivers shaping the corneal ulcer pipeline? Click here: https://www.delveinsight.com/report-store/corneal-ulcer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Corneal Ulcer Pipeline Report
• DelveInsight's corneal ulcer pipeline analysis depicts a strong space with 15+ active players working to develop 15+ pipeline drugs for corneal ulcer treatment.
• The leading corneal ulcer companies include OcuNexus Therapeutics, Recordati Rare Diseases, Santen S.A.S., FirstString Research, Regeneratetx, Stuart Therapeutics, EyeGate Pharmaceuticals, Trefoil Therapeutics, AmebaGone Inc, Dobecure, Editas Medicine, and others are evaluating their lead assets to improve the corneal ulcer treatment landscape.
• Key corneal ulcer pipeline therapies in various stages of development include MPC-06-ID, LY3016859, PP353, CordSTEM-DD, ALLOD 2, STA 363, XG005, SX600, CAM2038, and others.
• In May 2025, the FDA granted Fast Track designation to urcosimod (OKYO Pharma) for treating neuropathic corneal pain, which often accompanies chronic epithelial defects and ulcerative conditions. The Phase 2b trial began dosing in October 2024
• In May 2025, Blue Cross Blue Shield guidelines reaffirmed approval of cenegermin‐bkjl (Oxervate®)-recombinant human nerve growth factor-for neurotrophic keratitis, a condition that can result in persistent corneal ulcers. Originally FDA-approved in August 2018 with orphan status
• In February 2025, the FDA issued a Day‐74 letter accepting the NDA for Epioxa (epi‐on corneal cross‐linking) from Glaukos, with a PDUFA target date of October 20, 2025. Epioxa represents the first non‐invasive, epi‐on drug/device therapy intended to strengthen corneal tissue in keratoconus and potentially related ulcerative complications

Request a sample and discover the recent breakthroughs happening in the corneal ulcer pipeline landscape at https://www.delveinsight.com/report-store/corneal-ulcer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Corneal Ulcer Overview
A corneal ulcer is an open sore on the cornea, the clear front surface of the eye. It is most commonly caused by infections-bacterial, viral, fungal, or parasitic-but can also result from eye injuries, contact lens misuse, or severe dry eye. Symptoms typically include eye redness, pain, tearing, blurred vision, light sensitivity, and a visible white spot on the cornea. If left untreated, corneal ulcers can lead to serious complications, including vision loss or blindness. Treatment depends on the underlying cause and often involves antibiotic, antifungal, or antiviral eye drops. In severe cases, surgery such as corneal transplantation may be necessary. Early diagnosis and prompt treatment are crucial for preserving vision.

Find out more about corneal ulcer medication at https://www.delveinsight.com/report-store/corneal-ulcer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Corneal Ulcer Treatment Analysis: Drug Profile
CODA001: OcuNexus Therapeutics
CODA001 is an antisense oligonucleotide that downregulates connexin 43 (Cx43), a gap junction protein elevated in persistent epithelial defects. Originally developed by CODA Therapeutics and now in Phase II under OcuNexus, the drug has shown promise in patients with severe ocular surface burns. In a study by Ormonde et al., five refractory cases were treated using Cx43-specific antisense oligonucleotides in Poloxamer407 gel, resulting in reduced inflammation within 1-2 days and complete corneal reepithelialization.

Synthetic FGF Inhibitors: Dobecure
Dobecure is developing synthetic fibroblast growth factor (FGF) inhibitors for conditions like age-related macular degeneration (wet and dry), uveitis, corneal edema, herpetic keratitis, and more. The drug is currently in Phase I development, targeting inflammatory and degenerative eye disorders.

Learn more about the novel and emerging corneal ulcer pipeline therapies at https://www.delveinsight.com/report-store/corneal-ulcer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Corneal Ulcer Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Infusion
• Intradermal
• Intramuscular
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical

By Molecule Type
• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies

Scope of the Corneal Ulcer Pipeline Report
• Coverage: Global
• Key Corneal Ulcer Companies: OcuNexus Therapeutics, Recordati Rare Diseases, Santen S.A.S., FirstString Research, Regeneratetx, Stuart Therapeutics, EyeGate Pharmaceuticals, Trefoil Therapeutics, AmebaGone Inc, Dobecure, Editas Medicine, and others.
• Key Corneal Ulcer Pipeline Therapies: MPC-06-ID, LY3016859, PP353, CordSTEM-DD, ALLOD 2, STA 363, XG005, SX600, CAM2038, and others.

To dive deep into rich insights for drugs used for corneal ulcer treatment, visit: https://www.delveinsight.com/report-store/corneal-ulcer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Corneal Ulcer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Corneal Ulcer Pipeline Therapeutics
6. Corneal Ulcer Pipeline: Late-Stage Products (Phase III)
7. Corneal Ulcer Pipeline: Mid-Stage Products (Phase II)
8. Corneal Ulcer Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Corneal Ulcer Pipeline Insight 2025: 15+ Emerging Anti-Infective and Regenerative Therapies Targeting Sight-Threatening Infections | DelveInsight here

News-ID: 4112506 • Views:

More Releases from DelveInsight

Cystinuria Pipeline Insight 2025: Redefining Treatment through Precision Therapies and Rare Disease Innovation | DelveInsight
Cystinuria Pipeline Insight 2025: Redefining Treatment through Precision Therapi …
DelveInsight's "Cystinuria - Pipeline Insight, 2025" provides a detailed examination of the ongoing therapeutic R&D landscape targeting cystinuria, a rare inherited disorder characterized by defective renal reabsorption of cystine and other dibasic amino acids, leading to recurrent kidney stone formation. The disease is driven by mutations in the SLC3A1 or SLC7A9 genes, and remains a chronic urological challenge due to its lifelong recurrence risk and resistance to standard stone-prevention strategies. Current
Cystinosis Pipeline Insight 2025: Advancing Beyond Cysteamine to Target the Root Cause of Disease | DelveInsight
Cystinosis Pipeline Insight 2025: Advancing Beyond Cysteamine to Target the Root …
DelveInsight's "Cystinosis - Pipeline Insight, 2025" offers an in-depth overview of the evolving therapeutic landscape for this ultra-rare lysosomal storage disorder caused by mutations in the CTNS gene, leading to dysfunctional cystine transport and accumulation within lysosomes. This systemic metabolic disease predominantly affects the kidneys, eyes, and endocrine system, with nephropathic cystinosis being the most severe and common form. The current treatment paradigm is centered on cysteamine therapy, which helps deplete
CDKL5 Deficiency Disorder Pipeline Insight 2025: Progress from Seizure Control to Precision Therapies | DelveInsight
CDKL5 Deficiency Disorder Pipeline Insight 2025: Progress from Seizure Control t …
Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder is a rare X-linked neurodevelopmental condition caused by mutations in the CDKL5 gene, leading to early-onset, treatment-resistant epilepsy and severe cognitive and motor impairment. The disorder primarily affects females and typically presents within the first few months of life with frequent seizures, profound hypotonia, and significant developmental delays. As awareness and genetic diagnostic capabilities improve, the number of accurately diagnosed CDKL5 cases continues to
Mesothelioma Pipeline Insight 2025: Emerging Immunotherapies and Targeted Agents Aim to Redefine Outcomes in an Aggressive Cancer | DelveInsight
Mesothelioma Pipeline Insight 2025: Emerging Immunotherapies and Targeted Agents …
DelveInsight's "Mesothelioma - Pipeline Insight, 2025" report offers a detailed overview of the clinical and developmental pipeline for mesothelioma-an aggressive and rare cancer primarily linked to asbestos exposure, with poor prognosis and limited treatment options. Despite decades of therapeutic stagnancy, 2025 marks a pivotal point in mesothelioma research, with a growing pipeline of novel agents targeting both tumor biology and the tumor microenvironment. Standard therapies such as chemotherapy and surgery have

All 5 Releases


More Releases for Corneal

Evolving Market Drivers In The Corneal Topographers Industry: Rising Prevalence …
The Corneal Topographers Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Corneal Topographers Market Size During the Forecast Period? The corneal topographers market has grown strongly in recent years. It will grow from $0.88 billion in 2024 to $0.93 billion in 2025,
Key Influencer in the Corneal Topographers Market 2025: Rising Prevalence Of Eye …
What Is the Forecasted Market Size and Growth Rate for the Corneal Topographers Market? The market for corneal topographers has experienced robust growth in the past few years. The market size is expected to rise from $0.88 billion in 2024 to $0.93 billion in 2025, showing a compound annual growth rate (CAGR) of 6.5%. Factors contributing to the growth observed in the historic period include a rise in the number of
Corneal Topographers Market Insights, Forecast to 2033
The new report published by The Business Research Company, titled Corneal Topographers Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends. As per the report, the corneal topographers market size has grown strongly in recent years. It will grow from $0.83 billion in 2023
Corneal Topographers Market A Clearer View of Corneal Disease: How Corneal Topog …
Corneal Topographers Market Corneal Topographers Market to reach over USD 1,051.91 Million by the year 2031 - Exclusive Report by InsightAce Analytic "Corneal Topographers Market" in terms of revenue was estimated to be worth USD 738.36 Million in 2023 and is poised to reach USD 1,051.91 Million by 2031, growing at a CAGR of 4.65% from 2024 to 2031 according to a new report by InsightAce Analytic. Request for free Sample Pages:
Corneal Topographers Market Development, Trends, Segmentations Analysis
Transparency Market Research (TMR) has published a new report on the corneal topographers market for the forecast period of 2019-2027. • According to the report, the global corneal topographers market was valued at ~US$ 920 Mn in 2018, and is projected to expand at a CAGR of 5% from 2019 to 2027. The global corneal topographers market is driven by an increase in the awareness and acceptance of corneal topographers due to
01-21-2022 | Health & Medicine
SDKI
Artificial Corneal and Corneal Implant Market 2022 Industry Key Player, Trend an …
SDKI Inc. aims to provide a detailed analysis of several aspects of the market, including market growth drivers, opportunities, recent trends and challenges between 2021 and 2026. The artificial corneal and corneal implant market. Report sample URL https://www.sdki.jp/sample-request-112023 The global artificial corneal and corneal implant market is estimated to reach US $ 599 million by 2026 from US $ 418 million in 2021 and is projected to grow at a CAGR of 7.4%